{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:29Z","timestamp":1786118849740,"version":"build-2736575974"},"reference-count":35,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2508200"],"award-info":[{"award-number":["2023YFC2508200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shaanxi Health Commission","award":["2024TD-15"],"award-info":[{"award-number":["2024TD-15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Targeted systemic therapies for atopic dermatitis (AD), including biologics and Janus kinase inhibitors, are increasingly used. However, comparative postmarketing evidence on herpetic infection-related safety signals across these therapies remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare safety signals of herpetic infections associated with targeted AD therapies using the Food and Drug Administration Adverse Event Reporting System (FAERS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>FAERS reports (Q2 2017 to Q1 2025) involving dupilumab, abrocitinib, baricitinib or upadacitinib were included if these agents were designated as the primary suspect drug and the indication was AD. Disproportionality analyses using four algorithms were performed to detect signals for overall and virus-specific herpetic events. Subgroup analyses by age, sex and time to onset (TTO) were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All therapies demonstrated positive signals for herpetic infections. Baricitinib and abrocitinib showed the strongest signals, followed by upadacitinib, whereas dupilumab showed comparatively lower signals overall. Notably, dupilumab demonstrated a herpes simplex virus (HSV) signal comparable with abrocitinib and higher than for upadacitinib, and a signal for eczema herpeticum (EH) was also identified. Signals were generally higher in female patients, except for upadacitinib. Age-stratified analyses showed varying signal patterns across age groups. The median TTO differed between therapies, with an earlier onset for upadacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reporting patterns of herpetic infections differ across targeted AD therapies. Disproportionate reporting of HSV and EH with dupilumab warrants further investigation. Differences across sex, age and TTO suggest potential heterogeneity in reporting patterns, which may reflect underlying patient characteristics and reporting behaviours.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ced\/llag242","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:43:14Z","timestamp":1780746194000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative pharmacovigilance of herpetic infections with dupilumab and Janus kinase inhibitors in atopic dermatitis"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2664-8069","authenticated-orcid":false,"given":"Yaning","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Dermatology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyang","family":"Hong","sequence":"additional","affiliation":[{"name":"Xi\u2019an Jiaotong University Health Science Center , Xi\u2019an ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfang","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Luo","sequence":"additional","affiliation":[{"name":"Core Research Laboratory, The Second Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3493-7198","authenticated-orcid":false,"given":"Yumin","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Dermatology, the Second Affiliated Hospital of Xi\u2019an Jiaotong University , Xi\u2019an ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2026080612565605200_llag242-B1","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3390\/cells13050425","article-title":"Unraveling atopic dermatitis: insights into pathophysiology, therapeutic advances, and future perspectives","volume":"13","author":"Pareek","year":"2024","journal-title":"Cells"},{"key":"2026080612565605200_llag242-B2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"key":"2026080612565605200_llag242-B3","doi-asserted-by":"crossref","first-page":"1159404","DOI":"10.3389\/fmolb.2023.1159404","article-title":"The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis \u2013 an update","volume":"10","author":"\u00c7etinarslan","year":"2023","journal-title":"Front Mol Biosci"},{"key":"2026080612565605200_llag242-B4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.jaci.2025.01.013","article-title":"Update on atopic dermatitis","volume":"155","author":"Meledathu","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026080612565605200_llag242-B5","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jdv.20724","article-title":"The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: a global cohort study","volume":"39","author":"Kridin","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026080612565605200_llag242-B6","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/all.16495","article-title":"Real-world efficacy and safety of abrocitinib in Chinese atopic dermatitis patients: a single-centre prospective study","volume":"80","author":"Li","year":"2025","journal-title":"Allergy"},{"key":"2026080612565605200_llag242-B7","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s13555-025-01425-y","article-title":"Real-world evidence for baricitinib in the treatment of atopic dermatitis and alopecia areata: systematic literature review 2020\u20132023","volume":"15","author":"Seneschal","year":"2025","journal-title":"Dermatol Ther"},{"key":"2026080612565605200_llag242-B8","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.3390\/jcm14092953","article-title":"Real-world effectiveness and safety of upadacitinib and abrocitinib in moderate-to-severe atopic dermatitis: a 52-week retrospective study","volume":"14","author":"Ibba","year":"2025","journal-title":"J Clin Med"},{"key":"2026080612565605200_llag242-B9","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1111\/all.14853","article-title":"Eczema herpeticum in atopic dermatitis","volume":"76","author":"Traidl","year":"2021","journal-title":"Allergy"},{"key":"2026080612565605200_llag242-B10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMc1700366","article-title":"Two phase 3 trials of dupilumab vs. placebo in atopic dermatitis","volume":"376","author":"Mennini","year":"2017","journal-title":"N Engl J Med"},{"key":"2026080612565605200_llag242-B11","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab vs. placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026080612565605200_llag242-B12","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib vs. placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"2026080612565605200_llag242-B13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.21630","article-title":"Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4)","volume":"187","author":"Bieber","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026080612565605200_llag242-B14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"2026080612565605200_llag242-B15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s40257-019-00445-7","article-title":"Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis","volume":"20","author":"Eichenfield","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2026080612565605200_llag242-B16","first-page":"1010","article-title":"Retrospective analysis of adverse events with dupilumab reported to the United States Food and Drug Administration","volume-title":"J Am Acad Dermatol","author":"Wang","year":"2021"},{"key":"2026080612565605200_llag242-B17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1241954","article-title":"Risk of herpes zoster associated with JAK inhibitors in immune-mediated inflammatory diseases: a systematic review and network meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026080612565605200_llag242-B18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/14740338.2024.2355336","article-title":"Abrocitinib-associated adverse events: a real-world pharmacovigilance study using the FAERS database","volume":"24","author":"Sun","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2026080612565605200_llag242-B19","doi-asserted-by":"crossref","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","article-title":"A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib","volume":"14","author":"Wu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026080612565605200_llag242-B20","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70030","article-title":"Adverse event assessment of upadacitinib: a pharmacovigilance study based on the FAERS database","volume":"33","author":"Yuan","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026080612565605200_llag242-B21","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2026080612565605200_llag242-B22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s40264-025-01524-x","article-title":"Are causal statements reported in pharmacovigilance disproportionality analyses using individual case safety reports exaggerated in related citations? A meta-epidemiological study","volume":"48","author":"Bernardeau","year":"2025","journal-title":"Drug Saf"},{"key":"2026080612565605200_llag242-B23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40264-024-01433-5","article-title":"Comparators in pharmacovigilance: a quasi-quantification bias analysis","volume":"47","author":"Gravel","year":"2024","journal-title":"Drug Saf"},{"key":"2026080612565605200_llag242-B24","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026080612565605200_llag242-B25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41584-024-01153-1","article-title":"JAK inhibitor selectivity: new opportunities, better drugs?","volume":"20","author":"Virtanen","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"2026080612565605200_llag242-B26","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1093\/rheumatology\/keac710","article-title":"Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity","volume":"62","author":"Meudec","year":"2023","journal-title":"Rheumatology"},{"key":"2026080612565605200_llag242-B27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1698816","article-title":"Clinical updates of JAK inhibitors in cutaneous granulomatous diseases","volume":"16","author":"Gu","year":"2025","journal-title":"Front Immunol"},{"key":"2026080612565605200_llag242-B28","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-020-00527-x","article-title":"Dupilumab provides favorable safety and sustained efficacy for up to 3\u2005years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"21","author":"Beck","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2026080612565605200_llag242-B29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40257-022-00685-0","article-title":"Dupilumab provides acceptable safety and sustained efficacy for up to 4\u2005years in an open-label study of adults with moderate-to-severe atopic dermatitis","volume":"23","author":"Beck","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2026080612565605200_llag242-B30","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/bjd.18179","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: daily practice data","volume":"182","author":"de Wijs","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026080612565605200_llag242-B31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"2026080612565605200_llag242-B32","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.jaci.2023.08.024","article-title":"Dupilumab strengthens herpes simplex virus type 1-specific immune responses in atopic dermatitis","volume":"152","author":"Traidl","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"2026080612565605200_llag242-B33","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1080\/21645515.2020.1847582","article-title":"A systematic literature review of herpes zoster incidence worldwide","volume":"17","author":"van Oorschot","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"2026080612565605200_llag242-B34","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s40121-024-01002-4","article-title":"The incidence of herpes zoster complications: a systematic literature review","volume":"13","author":"Giannelos","year":"2024","journal-title":"Infect Dis Ther"},{"key":"2026080612565605200_llag242-B35","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s15010-023-02156-y","article-title":"Risk factors for herpes zoster infections: a systematic review and meta-analysis unveiling common trends and heterogeneity patterns","volume":"52","author":"Steinmann","year":"2024","journal-title":"Infection"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag242\/68487135\/llag242.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llag242\/68487135\/llag242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:57:10Z","timestamp":1786035430000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/advance-article\/doi\/10.1093\/ced\/llag242\/8703648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1093\/ced\/llag242","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"llag242"}}